RxDoctor Payments Data

Teresa Mullins, APRN

Family · Huntington, WVNPI 1801180724

Payments from drug & device makers

$1,804in general payments, 2019–2025

Across 81 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$378
  • AbbVie$374
  • Phathom Pharmaceuticals, Inc.$212
  • Madrigal Pharmaceuticals$144
  • Ipsen Biopharmaceuticals, Inc$129
  • Pfizer$94
  • plus $474 from 12 others

What the payments were for

  • Food & beverage$1,804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,804 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$13,909
Medicare patients
127
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$301,521
XifaxanRifaximin55$180,760
LinzessLinaclotide53$50,820
TrulancePlecanatide19$17,437
ErythromycinErythromycin Base13$10,411
Dexlansoprazole DrDexlansoprazole14$3,378
Famotidine241$3,227
Lubiprostone22$2,811
Omeprazole152$1,778
Pantoprazole Sodium169$1,599
Dicyclomine Hcl67$1,597
Sucralfate39$1,198
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl52$1,142
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$878
Lactulose24$725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$378$198,19774 claims
AbbVieLinzess$374$50,82053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →